Latest News
Late-Breaking HOPA News: Fam-trastuzumab deruxtecan-nxki for HER2 Ultralow Metastatic Breast Cancer
The ability of fam-trastuzumab deruxtecan-nxki to treat breast cancer patients with HER2 IHC 0 with positive membrane staining up to IHC 3+ has changed the treatment paradigm for metastatic disease.
Pharmacist's Application to Practice: Sacituzumab govitecan-hziy
Brooke Kielkowski, PharmD, PGY2 Oncology Pharmacy Resident, and Jordan Hill, PharmD, BCOP, Pharmacy Clinical Specialist, both from WVU Medicine - West Virginia University Hospitals, Morgantown, WV, write about sacituzumab govitecan-hziy (Trodelvy).
Pharmacist's Application to Practice: Zolbetuximab-clzb
Olivia Tholt, PharmD, PGY2 Oncology Pharmacy Resident, and Sarah Cimino, PharmD, BCOP, Clinical Pharmacist Specialist, Gastrointestinal Oncology, both from Vanderbilt University Medical Center, Nashville, TN, write about zolbetuximab-clzb (Vyloy).
Explore more from HOPA
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously